Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3258)
Drug Name
Remogliflozin etabonate
Prodrug Info Remogliflozin etabonate is the prodrug of Remogliflozin
Synonyms GSK-189075; GSK-189075A; KGT-1681
Indication Type-1/2 diabetes [ICD11: 5A10-5A11] Phase 2 [1]
Type-2 diabetes [ICD11: ICD11: 5A11] Phase 2 [2]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 522.6 Topological Polar Surface Area 142
Heavy Atom Count 37 Rotatable Bond Count 12
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 10
Cross-matching ID
PubChem CID
9871420
CAS Number
442201-24-3
TTD Drug ID
D0V4MB
Formula
C26H38N2O9
Canonical SMILES
CCOC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O
InChI
InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
InChIKey
UAOCLDQAQNNEAX-ABMICEGHSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Remogliflozin DM015537
9846588
Unclear - Unclear 1 [3]
GSK1132678 DM017358 N. A. Unclear - Unclear 2 [3]
GSK1997714 DM017362 N. A. Unclear - Unclear 2 [3]
GSK279782 DM015522
9801558
Unclear - Unclear 2 [3]
GSK333081 DM015593
10001485
Unclear - Unclear 2 [3]
GSK1997711 DM017359 N. A. Unclear - Unclear 3 [3]
GSK355993 DM017360 N. A. Unclear - Unclear 3 [3]
Remogliflozin etabonate metabolite M13 DM017361 N. A. Unclear - Unclear 3 [3]
GSK355993 DM017360 N. A. Unclear - Unclear 4 [3]
Remogliflozin etabonate metabolite M13 DM017361 N. A. Unclear - Unclear 4 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR008486 Remogliflozin etabonate Remogliflozin Unclear - Unclear ES [3]
MR008487 Remogliflozin GSK1132678 Unclear - Unclear GLYB [3]
MR008491 Remogliflozin GSK279782 Unclear - Unclear CYP3A4 ... [3]
MR008493 Remogliflozin GSK333081 Unclear - Unclear CYP3A4 [3]
MR008495 Remogliflozin GSK1997714 Unclear - Unclear Unclear [3]
MR008488 GSK1132678 GSK1997711 Unclear - Unclear UGT [3]
MR008492 GSK279782 GSK355993 Unclear - Unclear GLYB [3]
MR008494 GSK333081 Remogliflozin etabonate metabolite M13 Unclear - Unclear GLYB [3]
MR008489 GSK1997711 GSK355993 Unclear - Unclear CYP [3]
MR008490 GSK1997711 Remogliflozin etabonate metabolite M13 Unclear - Unclear Unclear [3]
⏷ Show the Full List of 10 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Beta-glycosidase (glyB) DME1677 Parabacteroides distasonis
A0A3D9A9X6_9BACT
3.2.1.-
[3]
Cytochrome P450 (CYP) DMEN060 . Not Available Not Available [3]
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
Esterases (ES) DMEN229 Homo sapiens Not Available Not Available [3]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[3]
UDP-glucuronyltransferase (UGT) DMEN064 . Not Available Not Available [3]
⏷ Show the Full List of 7  DME(s)
References
1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021813)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.